Department of Internal Medicine "D", Sheba Medical Center, Tel Hashomer, Ramat Gan 52621, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Nutrients. 2021 Mar 2;13(3):812. doi: 10.3390/nu13030812.
We aimed to investigate the prevalence of decreased folate levels in patients hospitalized with Coronavirus Disease 2019 (COVID-19) and evaluate their outcome and the prognostic signifi-cance associated with its different levels. In this retrospective cohort study, data were obtained from the electronic medical records at the Sheba Medical Center. Folic acid levels were available in 333 out of 1020 consecutive patients diagnosed with COVID-19 infection hospitalized from January 2020 to November 2020. Thirty-eight (11.4%) of the 333 patients comprising the present study population had low folate levels. No significant difference was found in the incidence of acute kidney injury, hypoxemia, invasive ventilation, length of hospital stay, and mortality be-tween patients with decreased and normal-range folate levels. When sub-dividing the study population according to quartiles of folate levels, similar findings were observed. In conclusion, decreased serum folate levels are common among hospitalized patients with COVID-19, but there was no association between serum folate levels and clinical outcomes. Due to the important role of folate in cell metabolism and the potential pathologic impact when deficient, a follow-up of folate levels or possible supplementation should be encouraged in hospitalized COVID-19 patients. Fur-ther studies are required to assess the prevalence and consequences of folate deficiency in COVID-19 patients.
我们旨在调查在因 2019 年冠状病毒病(COVID-19)住院的患者中叶酸水平降低的患病率,并评估其结局以及与不同叶酸水平相关的预后意义。在这项回顾性队列研究中,数据来自 Sheba 医疗中心的电子病历。在 2020 年 1 月至 2020 年 11 月期间因 COVID-19 感染住院的 1020 例连续患者中,有 333 例获得了叶酸水平数据。本研究人群中 38 例(11.4%)患者的叶酸水平较低。在叶酸水平降低和正常范围内的患者之间,急性肾损伤、低氧血症、有创通气、住院时间和死亡率的发生率没有差异。根据叶酸水平的四分位区间对研究人群进行细分后,也观察到了类似的结果。总之,COVID-19 住院患者中血清叶酸水平降低很常见,但血清叶酸水平与临床结局之间没有关联。由于叶酸在细胞代谢中的重要作用以及缺乏时的潜在病理影响,应鼓励 COVID-19 住院患者随访叶酸水平或可能进行补充。需要进一步的研究来评估 COVID-19 患者中叶酸缺乏的发生率和后果。